Nanocarry Therapeutics

Cover Block

Attribute	Value
Name	Nanocarry Therapeutics
Tagline	Developing a nanoparticle platform to deliver biologic drugs across the blood-brain barrier for neuro-oncology and CNS indications.
Headquarters	Weizmann Science Park, Israel
Founded	2021
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout

Links

• Website: https://nanocarry.com/
• LinkedIn: https://il.linkedin.com/company/nanocarry-therapeutics

The Short Version

Nanocarry Therapeutics is a preclinical Israeli biotech developing a nanoparticle platform to deliver biologic drugs across the blood-brain barrier. The company’s AxS platform uses a gold nanoparticle core engineered to bind therapeutic antibodies and exploit insulin pathways for transport, with preclinical data suggesting it can deliver up to 30 times more antibody to the brain than standard methods [Bar-Ilan University]. Founded in 2021 as a spinout from Bar-Ilan University, the company’s initial focus is on brain metastases from HER2-positive breast cancer and non-small-cell lung cancer. The business model is B2B, with the implied path being partnership with larger pharmaceutical companies. Public data on funding is sparse, with no verifiable press releases detailing round amounts, dates, or lead investors [Tracxn].

Data Accuracy: YELLOW -- Core platform claims are well-sourced from university and company materials, but key financial and team details lack independent corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Biotech / Life Sciences
Technology Type	Deeptech
Geography	Middle East / North Africa
Growth Profile	Venture Scale
Founding Team	Academic Spinout

The Company in Brief

Nanocarry Therapeutics is an Israeli preclinical biotechnology company founded in 2021, operating from the Weizmann Science Park [LinkedIn]. The company was established to commercialize academic research focused on breaching the blood-brain barrier, specifically originating from Bar-Ilan University [Bar-Ilan University]. Its core mission is to develop a platform technology that makes brain tumors and central nervous system diseases accessible to biologic drugs.

Since its founding, the company's primary disclosed milestone is the development of its AxS nanoparticle platform to a preclinical stage. Research published by the affiliated university indicates preclinical studies demonstrating the platform's ability to deliver significantly higher concentrations of therapeutic antibodies to the brain compared to standard methods [Bar-Ilan University]. A subsequent signal of external validation came in 2022, when the company's brain-penetrating nanoplatform was selected for an unspecified program aimed at improving therapy delivery [FirstWord Pharma, 2022].

Operational details remain limited. The company maintains a small team, with public data suggesting a headcount between 2 and 20 employees [LinkedIn][Prospeo]. Senior leadership includes Michal Roytman, who is listed as Chief Business Officer [Synapse-Patsnap].

Data Accuracy: YELLOW -- Core founding details are confirmed by the company's LinkedIn and university sources, but key operational and financial milestones lack independent public corroboration.

What They Have Built

The core of Nanocarry's proposition is a nanoparticle delivery platform designed to solve a specific, long-standing biophysical problem: transporting large biologic drugs across the blood-brain barrier. The company's AxS platform uses a gold nanoparticle core engineered to bind a therapeutic antibody on one side and exploit the body's own insulin transport mechanism on the other [Bar-Ilan University]. The company describes this as a "Plug and Play" system [LinkedIn].

Preclinical data cited by the originating university indicates a significant performance edge. Studies show the AxS platform can deliver up to 30 times more therapeutic antibodies to the brain compared to standard methods [Bar-Ilan University]. This claimed efficacy underpins the company's lead programs, which target brain metastases from HER2-positive breast cancer (candidate AxS-007) and non-small-cell lung cancer [Bar-Ilan University] [LinkedIn].

Data Accuracy: GREEN -- Platform claims and preclinical data are confirmed by the originating university and company materials.

Market Size and Demand

The global market for brain tumor treatments was valued at approximately $3.4 billion in 2022 and is projected to grow at a compound annual growth rate of 9.5% [Grand View Research, 2023]. The unmet need is pronounced; brain metastases occur in up to 30% of patients with solid tumors, and current systemic therapies often fail due to poor blood-brain barrier penetration [CNS Oncology, 2022].

Metric	Value
Global Brain Tumor Therapeutics (2022)	$3,400M
Projected CAGR (2023-2030)	9.5%

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broader sector report; specific platform TAM is not confirmed.

Who Else Is Fighting for This

Nanocarry's competitive landscape includes:

• Large Pharma Internal Programs. Companies such as Roche and AstraZeneca maintain R&D efforts to develop brain-penetrant versions of their antibody therapies [FirstWord Pharma].
• Specialized Biotech Platforms. Companies like Denali Therapeutics employ transport vehicle technology engineered to bind endogenous receptors for BBB crossing [Denali Therapeutics].
• Academic & Early-Stage Spinouts. Various groups explore nanoparticle, liposome, or focused ultrasound-mediated BBB disruption.

Nanocarry's defensible edge today rests on the specific engineering of its AxS platform: a gold nanoparticle core designed to "hitch a ride" with insulin receptors [Bar-Ilan University].

Data Accuracy: YELLOW -- Landscape analysis is inferred from public company pipelines and scientific literature; no direct competitive intelligence from Nanocarry is available.

Opportunity

The headline opportunity is to become the enabling platform for a new generation of brain-penetrant biologics. The company's cited preclinical evidence positions its AxS technology as a delivery system that could be licensed across multiple therapeutic areas [Bar-Ilan University].

Data Accuracy: YELLOW -- Opportunity analysis is based on cited platform claims and preclinical data; commercial traction and partnership details are not publicly available.

Sources

1. [LinkedIn] Nanocarry Therapeutics | https://il.linkedin.com/company/nanocarry-therapeutics
2. [Bar-Ilan University] The Israeli Startup That’s Breaching the Brain’s Defenses | https://www.biu.ac.il/en/article/583781
3. [Tracxn] NanoCarry - 2025 Company Profile, Team & Competitors | https://tracxn.com/d/companies/nanocarry/__KzBHeN2ttmdgpEu_iYKIvMdQYDQHKGuJkuIUpsYCSwM
4. [Prospeo] Nanocarry Therapeutics - Revenue, Employees, Funding, Acquisitions | https://prospeo.io/c/nanocarry-therapeutics-revenue
5. [Synapse-Patsnap] Nanocarry Therapeutics Contact Information | https://synapse-patsnap-com.libproxy1.nus.edu.sg/organization/e23bc986063c0e3fa84c504579d6a7d6
6. [Nanocarry] About - Nanocarry | https://nanocarry.com/about/
7. [Nanocarry] Nanocarry Therapeutics Pipeline | https://nanocarry.com/pipeline/
8. [FirstWord Pharma, 2022] FirstWord Pharma News | https://firstwordpharma.com/story/5892142
9. [Grand View Research, 2023] Brain Tumor Treatment Market Size Report | https://www.grandviewresearch.com/industry-analysis/brain-tumor-treatment-market
10. [CNS Oncology, 2022] Epidemiology of brain metastases | https://www.futuremedicine.com/doi/10.2217/cns-2021-0011
11. [FDA, 2024] Breakthrough Therapy Designations | https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
12. [Denali Therapeutics] Denali Therapeutics | https://www.denalitherapeutics.com/